The FDA issued this Revised Draft Guidance titled "

Guidance for Industry Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trial

" for the purpose of comment, and the purpose of the Guidance as stated by the FDA is "to assist sponsors in prospectively assessing the occurrence of treatment-emergent suicidal ideation and behavior in clinical trials of drug and biological products." Click the link to get to the PDF.